



26th July 2011

Liraglutide (Victoza®) for the treatment of adults with type 2 diabetes mellitus

The New Therapies Subgroup discussed the above drug at a meeting on the 28th July 2009 and 26th July 2011. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Liraglutide (Victoza®) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin or a sulphonylurea or metformin and a sulphonylurea or metformin and a thiazolidinedione.

The group recommends that liraglutide (Victoza®) may be considered as a treatment option as part of a triple therapy regimen for patients who are suitable for other GLP-1 mimetics (exenatide) as per NICE TA203 and CG87.

Please note Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes as per NICE TA203.

At current prices, the cost of one year's treatment with **exenatide 5 or 10 µg** twice daily is approx **£890** and the cost of one year's treatment with **liraglutide 1.2mg** daily is approx **£921**.

N.B Costs for liraglutide have been calculated using 3X3ml vials. If 2x3ml vials are used then costs may differ.

Review date: July 2013

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.